The European Union could give final approval for the Pfizer-BioNTech Covid-19 vaccine as early as December 23, a senior Commission official said on Wednesday, only two days after a possible green light from the bloc's regulator.
Under EU rules, the European Medicines Agency (EMA) recommends the approval of new medicines and vaccines, but the final decision to allow them onto the market is made by the EU Executive Commission after consultation with EU governments.
The EMA said on Tuesday it could issue a recommendation on the Pfizer-BioNTech vaccine on December 21.
Related Stories
Fosun Pharma to buy 100 mn doses of BioNTech's Covid-19 vaccine for mainland China
The vaccine developed by BioNTech and Pfizer has been administered to the public in Britain and the United States, and has received emergency-use approval in several other countries.“If this is the case, the European Commission is ready to provide the formal authorisation placing it in the market in supersonic, fast procedures,” Commission vice-president Margaritis Schinas told EU lawmakers.
“We can do it in two days,” he said, meaning final approval could come as early as December 23.
This further shortens the approval timetable after the EMA brought forward by more than a week its possible decision, originally planned for December 29. The Commission said last week it could approve vaccines within three days of approval by the EMA.
Britain and the US are among countries which have already approved the Pfizer/BioNTech vaccine.
Related Stories
Covid-19: Over 50% of US citizens unwilling to get vaccinated under emergency authorisation
The study finds that concerns about side effects were a significant barrierThe EMA usually takes at least seven months to issue a recommendation on vaccines after it receives full data from manufacturers, while the Commission can take as long as two months to authorise a vaccine after EMA approval.
If the EMA approves the vaccine on Monday, it will have taken just 20 days to assess the shot since it received data from large-clinical trials from Pfizer on December 1.
The approval would be a conditional authorisation, meaning the vaccine would continue to be strictly monitored for efficacy and possible side-effects.
Available data show that in the short term the vaccine is highly effective against the new coronavirus and causes only mild side-effects. But long-term data are not yet available.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.